Early Paxlovid treatment was associated with modestly lower risks of Long COVID, post-acute hospitalization, and death among high-risk, nonhospitalized patients with COVID-19

Researchers from UC San Francisco have found that Paxlovid treatment does not reduce the risk of developing long COVID. They also discovered a higher proportion of individuals with acute symptoms rebounding after treatment, and those who took Paxlovid were just as likely to develop severe Long COVID symptoms as those who did not.

A 15-day Paxlovid regimen was found to be safe for extended treatment, but did not show a clear reduction in select symptoms of long COVID. The trial enrolled 155 participants who had been infected with SARS-CoV-2 and reported moderate to severe long-COVID symptoms.

A new study published in eLife recommends taking Paxlovid three to five days after COVID-19 symptoms start to reduce viral loads and transmission. This optimal timing can help curb the spread of SARS-CoV-2 without population-wide restrictions.

New UCLA-led research finds that Paxlovid does not significantly reduce COVID-19 hospitalization and mortality among vaccinated older adults. The study suggests that Paxlovid's potential effect on COVID-19 hospitalization in vaccinated older adults is four times weaker than originally reported.

A clinical trial funded by NIH found that PAXLOVID does not improve Long COVID symptoms, but its extended duration did not cause serious side effects. The study recruited 959 patients and monitored symptoms over six months.

A recent case series suggests that an extended course of Paxlovid may help some patients with long Covid experience sustained improvements in their symptoms. The study, published in Communications Medicine, found that five out of 13 patients experienced significant symptom relief after taking the antiviral drug for 15 days.